For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 0 |
| Research and development | 344,955,000 | 101,644,000 | 63,806,000 | 54,234,000 |
| General and administrative | 48,387,000 | 49,277,000 | 37,021,000 | 16,121,000 |
| Total operating expenses | 393,342,000 | 150,921,000 | 100,827,000 | 70,355,000 |
| Loss from operations | -393,342,000 | -150,921,000 | -100,827,000 | -70,355,000 |
| Amortization of financing costs | 56,000 | 94,000 | 88,000 | 59,000 |
| Interest income, net | 33,704,000 | 40,940,000 | 15,020,000 | 1,589,000 |
| Realized loss on investments, net | - | - | 0 | -42,000 |
| Foreign exchange gain | - | - | 0 | 0 |
| Realized gain on investments, net | 55,000 | 112,000 | - | - |
| Total other income, net | 33,703,000 | 40,958,000 | 14,932,000 | 1,488,000 |
| Net loss | -359,639,000 | -109,963,000 | -85,895,000 | -68,867,000 |
| Unrealized gain (loss) on securities | 1,119,000 | -173,000 | 742,000 | -295,000 |
| Foreign currency translation loss | - | - | - | 258,000 |
| Foreign currency translation gain (loss) | 47,000 | -226,000 | -29,000 | - |
| Comprehensive loss | -358,473,000 | -110,362,000 | -85,182,000 | -69,420,000 |
| Denominator for basic net loss per share | 112,667,000 | 109,037,000 | 94,347,000 | 76,834,000 |
| Denominator for diluted net loss per share | 112,667,000 | 109,037,000 | 94,347,000 | 76,834,000 |
| Earnings per share, basic, total | -3.19 | -1.01 | -0.91 | -0.9 |
| Earnings per share, diluted, total | -3.19 | -1.01 | -0.91 | -0.9 |
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX)